NASDAQ:ADIL Adial Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adial Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.21 0.00 (0.00 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$1.20Now: $1.21▼$1.3950-Day Range$1.21MA: $1.44▼$1.9252-Week Range$1.00Now: $1.21▼$3.17Volume1.04 million shsAverage Volume443,031 shsMarket Capitalization$16.41 millionP/E RatioN/ADividend YieldN/ABeta0.83 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Adial Pharmaceuticals. Previous Next 2.0 Community Rank Outperform VotesAdial Pharmaceuticals has received 93 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAdial Pharmaceuticals has received 140 “underperform” votes. (Add your “underperform” vote.)Community SentimentAdial Pharmaceuticals has received 60.09% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Adial Pharmaceuticals and other stocks. Vote “Outperform” if you believe ADIL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADIL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAdial Pharmaceuticals does not currently pay a dividend.Dividend GrowthAdial Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 33.90% of the stock of Adial Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 5.92% of the stock of Adial Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Adial Pharmaceuticals is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adial Pharmaceuticals is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdial Pharmaceuticals has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.40 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADIL Previous Symbol CUSIPN/A CIK1513525 Webwww.adialpharma.com Phone434-422-9800Debt Debt-to-Equity RatioN/A Current Ratio13.88 Quick Ratio13.88Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book1.75Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-8,590,000.00 Net MarginsN/A Return on Equity-104.08% Return on Assets-96.46%Miscellaneous Employees3 Outstanding Shares13,561,000Market Cap$16.41 million Next Earnings Date11/12/2020 (Estimated) OptionableNot Optionable $1.21 0.00 (0.00 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ADIL News and Ratings via Email Sign-up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Adial Pharmaceuticals (NASDAQ:ADIL) Frequently Asked Questions How has Adial Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)? Adial Pharmaceuticals' stock was trading at $1.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADIL shares have decreased by 10.4% and is now trading at $1.21. View which stocks have been most impacted by COVID-19. When is Adial Pharmaceuticals' next earnings date? Adial Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for Adial Pharmaceuticals. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced its quarterly earnings data on Thursday, August, 13th. The company reported ($0.16) earnings per share (EPS) for the quarter. View Adial Pharmaceuticals' earnings history. Are investors shorting Adial Pharmaceuticals? Adial Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 514,800 shares, an increase of 97.6% from the August 15th total of 260,500 shares. Based on an average trading volume of 966,000 shares, the days-to-cover ratio is presently 0.5 days. View Adial Pharmaceuticals' Short Interest. Who are some of Adial Pharmaceuticals' key competitors? Some companies that are related to Adial Pharmaceuticals include Mereo BioPharma Group (MREO), Savara (SVRA), Aridis Pharmaceuticals (ARDS), KITOV PHARMA LT/S (KTOV), Eyenovia (EYEN), Infinity Pharmaceuticals (INFI), Entasis Therapeutics (ETTX), ASLAN PHARMACEU/ADR (ASLN), Aerpio Pharmaceuticals (ARPO), Aerpio Pharmaceuticals (ARPO), Anixa Biosciences (ANIX), Proteostasis Therapeutics (PTI), Monopar Therapeutics (MNPR), Citius Pharmaceuticals (CTXR) and Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM). View all competitors. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), AIM ImmunoTech (AIM), Aytu Bioscience (AYTU), T2 Biosystems (TTOO), Acasti Pharma (ACST), Biocept (BIOC), Inpixon (INPX) and Tandem Diabetes Care (TNDM). Who are Adial Pharmaceuticals' key executives? Adial Pharmaceuticals' management team includes the following people: Mr. William B. Stilley III, M.B.A., MBA, CEO, Pres, Sec., Treasurer & Director (Age 51)Prof. Bankole A. Johnson DSc, Ph.D., M.D., M.Phil, FRCPsych, Founder & Chief Medical Officer (Age 59)Mr. Joseph M. Truluck M.B.A., MBA, CFO & COO (Age 41)Ms. Monika Z. Rogozinska, Chief Devel. OfficerMr. Alex Lugovoy, Head of Strategy When did Adial Pharmaceuticals IPO? (ADIL) raised $8 million in an initial public offering on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager. What is Adial Pharmaceuticals' stock symbol? Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL." Who are Adial Pharmaceuticals' major shareholders? Adial Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bank of America Corp DE (1.12%). Company insiders that own Adial Pharmaceuticals stock include Bankole A Johnson, James W Jr Newman and William B Stilley III. View institutional ownership trends for Adial Pharmaceuticals. Which institutional investors are buying Adial Pharmaceuticals stock? ADIL stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE. Company insiders that have bought Adial Pharmaceuticals stock in the last two years include Bankole A Johnson, James W Jr Newman, and William B Stilley III. View insider buying and selling activity for Adial Pharmaceuticals. How do I buy shares of Adial Pharmaceuticals? Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Adial Pharmaceuticals' stock price today? One share of ADIL stock can currently be purchased for approximately $1.21. How big of a company is Adial Pharmaceuticals? Adial Pharmaceuticals has a market capitalization of $16.41 million. Adial Pharmaceuticals employs 3 workers across the globe. What is Adial Pharmaceuticals' official website? The official website for Adial Pharmaceuticals is www.adialpharma.com. How can I contact Adial Pharmaceuticals? Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The company can be reached via phone at 434-422-9800 or via email at [email protected] This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
